↑ トップへ　← 戻る

 Drug（薬物リスト） DrugBank | All Description Patterns💬 Info on mouse-over

e.g. Sirolimus, アダリムマブ

ABCDEFGH I JKLMNOPQRSTUVWXYZother

40 / 2,001 drugs

No. DrugBank 薬物名（臨床試験情報から抽出） KEGG DRUG KEGG GENES KEGG PATHWAY
On map, Yellow: Drug target genes		 指定難病告示番号
1Barium4件: Barium; Diagnostic test: barium esophagram; Procedure: speech and modified barium swallow study; Radiation: esophageal barium xray; - - - 2件: 19, 98 💬
2Beclomethasone dipropionate3件: Beclomethasone dipropionate; Combination product: beclomethasone dipropionate in addition to mc-evoo; Combination product: beclomethasone dipropionate in addition to refined oil; 2件: D00689
D07495 💬		 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 3件: 85, 97, 98 💬
3Benralizumab3件: Benralizumab; Biological: benralizumab, biological: placebo to mepolizumab; Biological: mepolizumab, biological: placebo to benralizumab; 1件: D09874 💬 1件: IL5RA 💬 4件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 4件: 44, 45, 98, 162 💬
4Bethanechol1件: Bethanechol; 1件: D01000 💬 5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 1件: 98 💬
5Budesonide49件: 0.5 mg budesonide effervescent tablet for orodispersible use; 1 mg budesonide effervescent tablet for orodispersible use; 1mg budesonide effervescent tablet for orodispersible use; 2mg budesonide effervescent tablet for orodispersible use; Budesonide; Budesonide ( zentacort capsules 3mg ); Budesonide (6 mg); Budesonide (9 mg); Budesonide 0.5mg orodispersible tablet twice daily; Budesonide 1mg orodispersible tablet twice daily; Budesonide 6 mg capsules, hard (bux-pvii prototype); Budesonide 6 mg prolonged-release capsule, hard (bux-pvii prototype); Budesonide 6 mg prolonged-release capsules, hard (bux-pvii prototype); Budesonide 9 mg capsules, hard (bux-pv); Budesonide 9 mg capsules, hard (bux-pvii prototype); Budesonide 9 mg prolonged-release capsule, hard (bux-pvii prototype); Budesonide 9 mg prolonged-release capsules, hard (bux-pvii prototype); Budesonide [0.4mg/ml] viscous suspension; Budesonide mmx; Budesonide mmx 6 mg tablet; Budesonide mmx®; Budesonide mmx® 6 mg; Budesonide mmx® 9 mg; Budesonide oral suspension; Budesonide oral suspension [0.2 mg/ml]; Budesonide plus prevacid; Budesonide-formoterol single inhaler; Budesonide-mmx; Budesonide-mmx®; Budesonide-mmx® 6 mg; Budesonide-mmx® 9 mg; Budesonide-mmx™; Budesonide/formoterol; Combination oral budesonide and rectal hydrocortisone; Formoterol/budesonide; High dose budesonide; High dose budesonide suspension; High dose budesonide tablet; High dose of budesonide; Inhaled/swallowed budesonide; Low dose budesonide; Low dose budesonide tablet; Methylprednisolone or budesonide; Oral budesonide; Oral budesonide suspension (mb-9); Oral budesonide suspension (obs); Oral viscous budesonide; Oral viscous budesonide (ovb); Viscous/swallowed budesonide; 1件: D00246 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 9件: 66, 93, 94, 95, 96, 97, 98, 228, 299 💬
6Cow milk-- - - 2件: 98, 210 💬
7Cromoglicic acid-2件: D00526
D07753 💬		 - - 3件:  2 , 85, 98 💬
8Dexlansoprazole1件: Dexlansoprazole; 1件: D08903 💬 2件: ATP4A, ATP4B 💬 4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 1件: 98 💬
9Diphenylpyraline-3件: D01172
D01627
D07862 💬		 1件: HRH1 💬 3件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 1件: 98 💬
10Dupilumab5件: Dupilumab; Dupilumab (blinded); Dupilumab (open-label); Dupilumab 300mg solution for injection; Dupilumab prefilled syringe; 1件: D10354 💬 1件: IL4R 💬 8件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 4件: 51, 98, 160, 162 💬
11Esomeprazole3件: Esomeprazole; Esomeprazole 20 mg; Nexium (esomeprazole magnesium); 4件: D01984
D04056
D07917
D09339 💬		 2件: ATP4A, ATP4B 💬 4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 6件: 13, 46, 86, 98, 298, 299 💬
12Famotidine2件: Famotidine; Famotidine 20 mg; 1件: D00318 💬 1件: HRH2 💬 3件: Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand-receptor interaction 4件:  6 , 46, 86, 98 💬
13Fluticasone7件: Fluticasone; Fluticasone mdi; Fluticasone propionate; Fluticasone propionate, 800 mcg twice daily (post 4fed failure); Fluticasone propionate, 880 mcg twice daily (after 6fed failure); Fluticasone propionate, usp; Swallowed fluticasone; 1件: D07981 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 3件: 98, 228, 299 💬
14Fluticasone propionate4件: Fluticasone propionate; Fluticasone propionate, 800 mcg twice daily (post 4fed failure); Fluticasone propionate, 880 mcg twice daily (after 6fed failure); Fluticasone propionate, usp; 1件: D01708 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 2件: 98, 228 💬
15Gold7件: Gold; Gold nanocrystals; Mtx goldshield tablets; Other: comparator: cpet cycle ergometer (gold standard); Procedure: quantiferon-tb gold assay; Procedure: repair of cdh w/sis gold; Sodium aurothiomalate (intramuscular gold); - - - 38件:  2 ,  5 ,  6 , 13, 17, 34, 46, 49, 50, 53, 65, 68, 76, 84, 86, 91, 93, 95, 96, 97, 98, 113, 158, 162, 171, 218, 222, 224, 227, 230, 271, 291, 294, 296, 298, 299, 310, 318 💬
16Honey3件: Device: manuka honey sinus rinse; Honey; Other: honey; 1件: D06776 💬 - - 3件: 57, 98, 299 💬
17Infliximab70件: 99m technetium infliximab; 99mtc-infliximab; Abp 710 - biosimilar to infliximab; Adalimumab and infliximab; Adalimumab, etanercept, golimumab or infliximab; Anti tnf therapy including infliximab; Anti-tnf: infliximab (infusion); Azathioprine or adalimumab and infliximab; Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Biosimilar infliximab; Ct-p13 sc (infliximab); Cyclosporine vs infliximab; Inflectra (infliximab); Infliximab; Infliximab (bcd-055); Infliximab (ifx alone); Infliximab (ifx); Infliximab (inf) + mtx, db; Infliximab (remicade); Infliximab (remicade): 100 mg of lyophilized infliximab; Infliximab + methotrexate (mtx); Infliximab 10 mg/kg; Infliximab 20 mg/kg; Infliximab 3 mg/kg; Infliximab 5 mg/kg; Infliximab 5 mg/kg body weight infused over 2 hours; Infliximab 5 mg/kg every 6 weeks; Infliximab 7 mg/kg every 8 weeks; Infliximab [infliximab biosimilar 3]; Infliximab and adalimumab; Infliximab and azathioprine combination at week 0; Infliximab and azathioprine combination at week 14; Infliximab and mtx; Infliximab biosimilar; Infliximab control; Infliximab group; Infliximab increased dose; Infliximab increased frequency; Infliximab infusion; Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab; Infliximab with azathioprine (iifx + aza); Infliximab+azathioprine; Infliximab, adalimumab, certolizumab pegol; Infliximab, azathioprine; Infliximab, etanercept; Infliximab, etanercept, adalimumab; Infliximab, methylprednisolone, methotrexate; Infliximab-biosimilar; Infliximab-eu; Infliximab-innovator; Infliximab-pfizer; Innovator infliximab; Intravitreal infliximab; Methotrexate + infliximab; Other: infliximab (ifx) infusion; Other: measurement of drug (adalimumab/infliximab); Procedure: measurement of serum infliximab and anti-infliximab antibodies; Procedure: treatment according to current standards without knowledge of serum infliximab and anti-infliximab ab status; Remicade (infliximab); Remicade® (infliximab); Remicaide (infliximab); Remsima (infliximab); Response to infliximab associated with methotrexate; Sb2 (infliximab biosimilar); Sb2 (proposed biosimilar to infliximab); Ta-650 (infliximab); Tnf blockers (infliximab, adalimumab, etanercept); Topical infliximab; Trexan+salazopyrin+oxiklorin+prednisolone + infliximab; Tumor necrosis factor inhibitor (etanercept, infliximab, adalimumab, and golimumab); 1件: D02598 💬 1件: TNF 💬 65件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
18Lansoprazole6件: Dexlansoprazole; Lansoprazole; Lansoprazole 30mg; Lansoprazole, amoxicillin, clarithromycin; Lansoprazole, clarithromycin, amoxycillin; Treat with lansoprazole 30 mg bid for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms; 1件: D00355 💬 2件: ATP4A, ATP4B 💬 4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 7件: 63, 71, 85, 98, 166, 222, 299 💬
19Loratadine1件: Loratadine; 1件: D00364 💬 1件: HRH1 💬 3件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 3件: 13, 46, 98 💬
20Losartan12件: Lisinopril, losartan, and atorvastatin; Losartan; Losartan and atenolol or propranolol; Losartan and nebivolol; Losartan and other angiotensin receptor blockers; Losartan bluefish 50 mg; Losartan hexal; Losartan potasico; Losartan potassium; Losartan tablets & qingremoshen granule; Other: losartan; Sildenafil and losartan; 2件: D00357
D08146 💬		 1件: AGTR1 💬 16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 18件: 17, 19, 36, 46, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 💬
21Mepolizumab7件: Biological: benralizumab, biological: placebo to mepolizumab; Biological: mepolizumab, biological: placebo to benralizumab; Mepolizumab; Mepolizumab (a-il-5 antibody); Mepolizumab 100 mg; Mepolizumab 300 mg; Sb-240563 (mepolizumab); 1件: D04923 💬 1件: IL5 💬 13件: Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 4件: 44, 45, 98, 162 💬
22Methamidophos-- - - 18件:  2 , 11, 13, 19, 46, 49, 58, 65, 70, 85, 86, 98, 113, 118, 129, 298, 299, 300 💬
23Mometasone2件: Mometasone; Mometasone furoate; 3件: D00690
D03325
D08227 💬		 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 2件: 98, 162 💬
24Mometasone furoate1件: Mometasone furoate; 1件: D00690 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 2件: 98, 162 💬
25Montelukast8件: 5 mg montelukast; Bms drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin); Montelukast; Montelukast sodium; Montelukast teva; Montelukast, flurbiprofen, midazolam, digoxin, pravastatin and bms-986142; Montelukast/ singulair; Singulair (montelukast sodium); 2件: D00529
D08229 💬		 1件: CYSLTR1 💬 2件: Calcium signaling pathway, Neuroactive ligand-receptor interaction 5件: 13, 46, 85, 98, 228 💬
26Nitric Oxide14件: Inhaled nitric oxide; Inhaled nitric oxide & inopulse delivery; Inhaled nitric oxide - 30 mcg/kg ibw/hr; Inhaled nitric oxide 5,10,15 mcg/kg ibw/hr; Inhaled nitric oxide 75 mcg/kg ibw/hr; Nitric oxide; Nitric oxide 160 ppm; Nitric oxide for inhalation; Nitric oxide generated by the geno nitrosyl delivery system; Nitric oxide plus oxygen; Nitric oxide supplement; Other: oral nitric oxide testing; Procedure: exhaled nitric oxide; Procedure: exhaled nitric oxide assessment; 1件: D00074 💬 - - 8件: 46, 85, 86, 98, 210, 251, 294, 299 💬
27Omalizumab4件: Omalizumab; Omalizumab (xolair); Recombinant humanized monoclonal antibody omalizumab to ige; Rituximab combined with omalizumab; 1件: D05251 💬 1件: FCER1A 💬 4件: Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway 7件: 46, 53, 65, 98, 162, 226, 299 💬
28Omeprazole19件: Bms drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin); Clartihromycin, amoxicillin, and omeprazole; Diclofenac + omeprazole; Dimebon + omeprazole; Esomeprazole; Esomeprazole 20 mg; Naproxen 500 mg tablets (pn 200 minus omeprazole); Nexium (esomeprazole magnesium); Omeprazole; Omeprazole (uk licensed generic product); Omeprazole 20 mg; Omeprazole 20mg; Omeprazole 20mg bid; Omeprazole 40 mg; Omeprazole 40mg capsule; Omeprazole magnesium; Omeprazole rectally 1mg/kg; Pn 200 tablets (500 mg naproxen and 20 mg omeprazole); Rifaximin+omeprazole+miralax; 4件: D00455
D01207
D05259
D05261 💬		 2件: ATP4A, ATP4B 💬 4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 16件:  6 ,  8 , 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299 💬
29Potassium5件: Dipotassium salt; Losartan potassium; Potassium; Potassium sparing diuretic; Potassium supplement; 1件: D08403 💬 - - 10件: 36, 46, 66, 67, 98, 115, 167, 179, 215, 235 💬
30Propofol5件: Device: propofol dosage; Intubated with propofol (ip); Procedure: sedation with iv propofol; Propofol; Propofol-lipuro; 1件: D00549 💬 16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 9件:  6 , 21, 22, 34, 46, 75, 84, 98, 296 💬
31Reslizumab1件: Reslizumab; 1件: D08985 💬 1件: IL5 💬 13件: Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 2件: 44, 98 💬
32Sevoflurane3件: Intubated with sevoflurane (is); Sevoflurane; Sevoflurane anesthetics; 1件: D00547 💬 - - 6件:  6 , 21, 22, 34, 98, 296 💬
33Sirolimus22件: Rapamycin, sirolimus; Sirolimus; Sirolimus (formerly known as rapamycin); Sirolimus (study drug)+ace inhibitor + statin; Sirolimus 0,1% crème; Sirolimus 0.2%; Sirolimus 0.4%; Sirolimus 1mg/ml; Sirolimus 2 mg; Sirolimus 2%; Sirolimus and hydroxychloroquine 200 mg; Sirolimus and hydroxychloroquine 400 mg; Sirolimus ointment; Sirolimus oral liquid product 1mg/ml; Sirolimus oral product; Sirolimus, 2%; Skincerity plus sirolimus/rapamycin; Skinercity plus sirolimus/rapamycin; Tavt-18 (sirolimus); Temsirolimus; Temsirolimus tablets; Topical 0.1% sirolimus; 1件: D00753 💬 1件: MTOR 💬 50件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
34Sucralfate1件: Sucralfate; 1件: D00446 💬 - - 1件: 98 💬
35Technetium Tc-99m-- - - 2件: 46, 98 💬
36Vitamin D36件: 10000iu vitamin d; 19 nor vitamin d; 25-hydroxyvitamin d3; 25oh-vitamin d; 5000iu vitamin d; Alendronate versus alfacalcidol (1-alpha oh vitamin d); Calcium and vitamin d combination; Cholecalciferol (vitamin d3); Cholecalciferol, vitamin d3; D6-25-hydroxyvitamin d3; Diagnostic test: vitamin d measurement; Ergocalciferol (vitamin d2); High-dose vitamin d (2000 iu per day); High-dose vitamin d3; Low dose arm receiving neutral oil and 400 iu/g of vitamin d every second day; Other: baseline serum vitamin d level at or above 50 nmol/l; Other: baseline serum vitamin d level below 50 nmol/l; Standard-dose vitamin d (400iu per day); Supplementation with vitamin d2/d3; Verum arm receiving vitamin d oil; Vitamin d; Vitamin d 100ug; Vitamin d 10ug; Vitamin d 25(oh)d; Vitamin d drops; Vitamin d in arm b; Vitamin d oil; Vitamin d powder; Vitamin d2; Vitamin d3; Vitamin d3 3000 ui daily; Vitamin d3 400 iu; Vitamin d3 4000 ui daily; Vitamin d3 6000 iu; Vitamin d3 800 ui/day then 800 ui/day; Vitamin d3: 3000 or 4000 ui/day then 2,000 ui/day; - - - 21件: 13, 19, 41, 43, 44, 46, 49, 50, 68, 93, 95, 96, 97, 98, 179, 222, 228, 235, 274, 298, 299 💬
37Vonoprazan1件: Vonoprazan; 1件: D11784 💬 2件: ATP4A, ATP4B 💬 4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 2件: 63, 98 💬
38Wheat3件: Other: antigen (wheat base soy sauce) spray; Other: wheat flour; Wheat; 1件: D06902 💬 - - 2件: 98, 266 💬
39Xanthan gum2件: Other: xanthan gum; Xanthan gum; 1件: D06333 💬 - - 1件: 98 💬
40Xylose2件: Other: d-xylose; Xylose; 1件: D06346 💬 - - 1件: 98 💬

先頭へ